Adicet Bio assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns assumed coverage of Adicet Bio (ACET) with a Buy rating and $4 price target The firm says preliminary data for ADI-270 in clear cell renal cell carcinoma is expected in the second half of 2025. It views the readout as a “partially risk-mitigated data catalyst” and says Adicet’s autoimmune program is a “free call option.”